返回
Strategies and testing methods for identifying mutagenic risks
DOI:10.1016/S0027-5107(00)00116-0.png)
摘要
En 中文
The evolution of testing strategies and methods for identification of mutagenic agents is discussed, beginning with the concern over potential health and population effects of chemical mutagens in the late 1940s that led to the development of regulatory guidelines for mutagenicity testing in the 1970s and 1980s. Efforts to achieve international harmonization of mutagenicity testing guidelines are summarized, and current issues and needs in the field are discussed, including the need for quantitative methods of mutagenic risk assessment, dose-response thresholds, indirect mechanisms of mutagenicity, and the predictivity of mutagenicity assays for carcinogenicity in vivo. Speculation is offered about the future of mutagenicity testing, including possible near-term changes in standard test batteries and the longer-term roles of expression profiling of damage-response genes, in vivo mutagenicity testing methods, and models that better account for differences in metabolism between humans and laboratory model systems. Published by Elsevier Science B.V.
Keyword:
mutagenicity
carcinogenicity
testing guidelines
harmonization
AI总结
对已上传原文的论文进行重点信息的提取,主要内容包括:简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
M
IF:
1.9
论文数:
44
被引数:
4.8K
机构
暂无机构信息
引用论文
Effect of mitogenic or regenerative cell proliferation on lacz mutant frequency in the liver of Muta™Mice treated with 5,9-dimethyldibenzo[c,g]carbazole
CARCINOGENESIS
IF2.9
How we treat invasive fungal diseases in patients with acute leukemia: the importance of an individualized approach
Blood
IF0
Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status
Tuberculosis
IF0
Aldosterone modulatesIfcurrent through gene expression in cultured neonatal rat ventricular myocytes

